Sarah Hardison is currently Therapeutic Area Director, Immunology & Immuno-oncology, for the Life Sciences business of Clarivate Analytics. Sarah works to help customers understand the drug development landscape in immuno-oncology and immunotherapy and represents the voice of industry in Clarivate’s products and services.
Prior to joining Clarivate, Sarah worked in product and portfolio management in Life Sciences reagents companies. She took on roles with increasing responsibility and thought leadership in immuno-oncology, establishing a pipeline of research-use antibodies against immunotherapy targets and developing a suite of preclinical screening services for immuno-oncology biologics.
Sarah earned her PhD in Immunology at the University of Texas followed by a postdoctoral fellowship at the University of Aberdeen, where she focused on the discovery and characterization of novel immune receptors. Her academic work led to 18 peer-reviewed publications, appearing in high-impact journals such as Nature, Nature Immunology, and Nature Microbiology